Tools / Drug approvals and letters / Drugs Venlafaxine Hydrochloride Treats major depressive disorder (MDD). Sold as Effexor, Effexor Xr, Venlafaxine Hydrochloride. Every FDA application for this active ingredient: 3 branded and 48 generic.
As of Nov 16, 2026, FDA lists 51 applications for Venlafaxine Hydrochloride (sold as Effexor, Effexor Xr, Venlafaxine Hydrochloride), first approved Dec 28, 1993, with 13 new uses approved and 0 published complete response letters.
First approved : Dec 28, 1993 Applications : 51 New uses approved : 13 Complete response letters : 0 Medicare spending, 2025 : $160M First approved in Japan : Sep 28, 2015
Medicare Spending CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Venlafaxine HCl ER Part D $120M +2% 1,007,589 Effexor XR Part D $21.6M -9% 2,527 Venlafaxine HCl Part D $18.1M +7% 164,629
What Pharmacies Pay Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change VENLAFAXINE HCL 100 MG TABLET: $0.120 per unit Generic · +8% in a year VENLAFAXINE HCL 25 MG TABLET: $0.071 per unit Generic · -4% in a year VENLAFAXINE HCL 37.5 MG TABLET: $0.074 per unit Generic · +2% in a year VENLAFAXINE HCL 50 MG TABLET: $0.085 per unit Generic · -2% in a year VENLAFAXINE HCL 75 MG TABLET: $0.086 per unit Generic · +3% in a year VENLAFAXINE HCL ER 150 MG CAP: $0.122 per unit Generic · -5% in a year VENLAFAXINE HCL ER 150 MG TAB: $0.226 per unit Generic · +8% in a year VENLAFAXINE HCL ER 225 MG TAB: $0.474 per unit Generic · -16% in a year VENLAFAXINE HCL ER 37.5 MG CAP: $0.079 per unit Generic · -12% in a year VENLAFAXINE HCL ER 37.5 MG TAB: $0.305 per unit Generic · -46% in a year VENLAFAXINE HCL ER 75 MG CAP: $0.080 per unit Generic · -12% in a year VENLAFAXINE HCL ER 75 MG TAB: $0.290 per unit Generic · -61% in a year Approvals in Japan (PMDA) First approved in Japan 261 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals Effexor SR, new ingredient Drugs with a new active ingredient indicated for the treatment of depression. · Pfizer Japan Inc. · Sep 28, 2015 Clinical Trials 27 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies · University of Michigan Phase 4 Not yet recruiting Aug 31, 2026 Biomarkers and Pharmacogenomics for Precision Depression Therapy Depression / Major Depressive Disorder · The Fourth Affiliated Hospital of Zhejiang University School of Medicine Not applicable Not yet recruiting Jul 31, 2026 Venlafaxine for Non-specific Low Back Pain Non-specific Low Back Pain, Pain Management · Beijing Tiantan Hospital Not applicable Not yet recruiting Jul 30, 2026 Venlafaxine Combined With Education and Behavioral Intervention for Bladder Pain Syndrome Bladder Pain Syndrome, Chronic Pelvic Nociplastic Pain · Beijing Tiantan Hospital Phase 1 Not yet recruiting Jul 13, 2026 Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) Migraine Associated Vertigo, Tinnitus · Stanford University Phase 4 Not yet recruiting Jun 17, 2026 Serotonin Norepinephrine Reuptake Inhibitors and the Risk of Serious Adverse Events Chronic Kidney Disease · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's — Active, not recruiting Apr 15, 2026 Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis Rheumatoid Arthritis · Ain Shams University Phase 2 Not yet recruiting Mar 27, 2026 The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster Herpes Zoster, Pain · Beijing Tiantan Hospital Not applicable Recruiting Jan 23, 2026
Applications NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Dec 28, 1993 Effexor NDA 20151 · New molecular entity Wyeth Pharms Inc52 Discontinued Oct 20, 1997 Effexor Xr NDA 20699 · New dosage form Upjohn79 Marketed Aug 3, 2006 Venlafaxine Hydrochloride ANDA 76690 Teva17 Marketed May 20, 2008 Venlafaxine Hydrochloride NDA 22104 · New dosage form Osmotica Pharm US13 Marketed Jun 13, 2008 Venlafaxine Hydrochloride ANDA 77515 Chartwell Rx4 Discontinued Jun 13, 2008 Venlafaxine Hydrochloride ANDA 77653 Zydus Pharms USA10 Marketed Jun 13, 2008 Venlafaxine Hydrochloride ANDA 78627 Sun Pharm Inds Inc6 Marketed Jun 13, 2008 Venlafaxine Hydrochloride ANDA 77166 Pharmobedient11 Discontinued Jun 13, 2008 Venlafaxine Hydrochloride ANDA 78301 Dr Reddys Labs Ltd10 Marketed Jan 9, 2009 Venlafaxine Hydrochloride ANDA 78554 Heritage8 Marketed Apr 7, 2010 Venlafaxine Hydrochloride ANDA 90555 Aurobindo Pharma7 Marketed May 11, 2010 Venlafaxine Hydrochloride ANDA 79098 Amneal Pharms8 Discontinued Jun 28, 2010 Venlafaxine Hydrochloride ANDA 76565 Teva14 Marketed Aug 4, 2010 Venlafaxine Hydrochloride ANDA 90027 Prinston7 Discontinued Aug 18, 2010 Venlafaxine Hydrochloride ANDA 91272 Sun Pharm8 Discontinued Dec 14, 2010 Venlafaxine Hydrochloride ANDA 78932 Alembic Pharms Ltd8 Marketed Apr 14, 2011 Venlafaxine Hydrochloride ANDA 78865 Sciegen Pharms1 Marketed Apr 14, 2011 Venlafaxine Hydrochloride ANDA 90174 Zydus Pharms USA Inc13 Marketed Apr 14, 2011 Venlafaxine Hydrochloride ANDA 200834 Aurobindo Pharma Ltd15 Marketed Apr 15, 2011 Venlafaxine Hydrochloride ANDA 90071 Valeant Pharms North0 Discontinued May 6, 2011 Venlafaxine Hydrochloride ANDA 78421 Dr Reddys Labs Ltd1 Marketed Jun 1, 2011 Venlafaxine Hydrochloride ANDA 78789 Pharmobedient8 Discontinued Jun 1, 2011 Venlafaxine Hydrochloride ANDA 90899 Torrent12 Discontinued Jul 11, 2011 Venlafaxine Hydrochloride ANDA 91123 Orbion Pharms5 Marketed Mar 16, 2012 Venlafaxine Hydrochloride ANDA 78087 Anchen Pharms3 Discontinued May 28, 2015 Venlafaxine Hydrochloride ANDA 202036 Yaopharma Co Ltd6 Marketed Mar 24, 2017 Venlafaxine Hydrochloride ANDA 205468 Mpp Pharma0 Marketed Oct 5, 2017 Venlafaxine Hydrochloride ANDA 204889 Macleods Pharms6 Marketed Nov 21, 2018 Venlafaxine Hydrochloride ANDA 206250 Cadila Pharms Ltd3 Marketed Nov 23, 2018 Venlafaxine Hydrochloride ANDA 201272 Platinum1 Marketed Jul 8, 2019 Venlafaxine Hydrochloride ANDA 212277 Annora Pharma3 Marketed Aug 29, 2019 Venlafaxine Hydrochloride ANDA 211323 Cadila Pharms Ltd2 Marketed Oct 31, 2019 Venlafaxine Hydrochloride ANDA 209193 Adaptis2 Discontinued Mar 12, 2020 Venlafaxine Hydrochloride ANDA 203332 Adaptis5 Marketed Oct 21, 2020 Venlafaxine Hydrochloride ANDA 214419 Ascent Pharms Inc1 Marketed Jan 21, 2021 Venlafaxine Hydrochloride ANDA 213927 Adaptis2 Discontinued Jun 10, 2021 Venlafaxine Hydrochloride ANDA 214127 Alkem Labs Ltd2 Marketed Jun 30, 2021 Venlafaxine Hydrochloride ANDA 214609 Somerset Theraps LLC1 Marketed Aug 6, 2021 Venlafaxine Hydrochloride ANDA 214654 Yichang Humanwell6 Marketed Jan 4, 2022 Venlafaxine Hydrochloride ANDA 214423 Pharmadax0 Discontinued Aug 30, 2022 Venlafaxine Hydrochloride ANDA 215622 Zydus Pharms1 Marketed Nov 28, 2022 Venlafaxine Hydrochloride ANDA 216044 Unique0 Marketed Apr 4, 2023 Venlafaxine Hydrochloride ANDA 200430 Nostrum Pharms LLC0 Discontinued Apr 12, 2023 Venlafaxine Hydrochloride ANDA 214691 Ajanta Pharma Ltd1 Marketed May 18, 2023 Venlafaxine Hydrochloride ANDA 217390 Granules1 Marketed Jun 6, 2024 Venlafaxine Hydrochloride ANDA 217767 Alembic0 Marketed Jan 28, 2025 Venlafaxine Hydrochloride ANDA 218180 Torrent0 Discontinued Feb 7, 2025 Venlafaxine Hydrochloride ANDA 217841 Abon Pharms LLC0 Marketed Nov 6, 2026 Venlafaxine Hydrochloride ANDA 220619 Yichang Humanwell0 Marketed — Venlafaxine Hydrochloride ANDA 78057 Impax Labs0 Discontinued — Venlafaxine Hydrochloride ANDA 78517 Pliva Hrvatska Doo0 Discontinued
Show all 51Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA